Belite Bio to Participate in the Benchmark's 4th Annual Healthcare House Call Investor ConferenceGlobeNewsWire • 05/14/24
Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/14/24
Belite Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor ConferenceGlobeNewsWire • 05/13/24
Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial ResultsGlobeNewsWire • 05/08/24
Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease (STGD1) and Geographic Atrophy (GA) and Perspectives On TinlarebantGlobeNewsWire • 05/06/24
Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual MeetingGlobeNewsWire • 05/06/24
Belite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 Annual MeetingGlobeNewsWire • 05/01/24
Does Belite Bio (BLTE) Have the Potential to Rally 41.14% as Wall Street Analysts Expect?Zacks Investment Research • 04/10/24
Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in JapanGlobeNewsWire • 03/22/24
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company WebsiteGlobeNewsWire • 03/12/24
Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/12/24
Belite Bio to Host Webcast on March 12, 2024, to Discuss Fourth Quarter and Full Year 2024 Financial ResultsGlobeNewsWire • 03/06/24
Belite Bio to Participate in the Leerink Partners Global Biopharma ConferenceGlobeNewsWire • 03/04/24
Belite Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceGlobeNewsWire • 02/07/24
Belite Bio to Participate in the Benchmark Company's Upcoming Discovery One-on-One Investor ConferenceGlobeNewsWire • 11/30/23
Belite Bio Reports Third Quarter 2023 Operational Highlights and Financial ResultsGlobeNewsWire • 11/14/23
Belite Bio to Host Webcast on November 14, 2023, to Discuss Third Quarter 2023 Financial ResultsGlobeNewsWire • 11/07/23
Belite Bio Presents Results from a 24-month, Phase 2 Study of Tinlarebant in Childhood-onset Stargardt Disease at the AAO Annual MeetingGlobeNewsWire • 11/06/23
Belite Bio Announces Presentation at the American Academy of Ophthalmology 2023 Annual MeetingGlobeNewsWire • 10/27/23
Belite Bio: The Pick Of The Post-IPO Biotechs - Is There Further Upside Ahead?Seeking Alpha • 08/22/23